Author

B. N. Bell

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 4 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Assay:proteomics· 5 Organism:human· 4 Research Focus:drug response / drug discovery· 3 Research Focus:host-pathogen & immune response· 2 Research Focus:cell type annotation· 1 Organism:mouse· 1 Organism:rat· 1

Frequent Co-Authors

P. S. Kim· 5 shared A. A. Rubio· 2 shared C. C. LaBranche· 2 shared D. C. Montefiori· 2 shared M. V. Filsinger Interrante· 2 shared A. E. Powell· 1 shared C. L. Brown· 1 shared C. Rodriguez· 1 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersImmunology

P. S. Kim

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

HIV-1 neutralization tiers are not relevant for inhibitors targeting the pre-hairpin intermediate

B. N. Bell, T. U. J. Bruun, N. Friedland, P. S. Kim

The paper shows that HIV-1 neutralization tiers do not predict the potency of inhibitors targeting the pre-hairpin intermediate, unlike broadly neutralizing antibodies.

bioRxiv · Oct 6, 2022 · PreprintImmunology

Converting non-neutralizing SARS-CoV-2 antibodies targeting conserved epitopes into broad-spectrum inhibitors through receptor blockade

P. A.-B. Weidenbacher, E. Waltari, I. de los Rios Kobara, B. N. Bell, J. E. Pak, P. S. Kim

This paper converts non-neutralizing SARS-CoV-2 antibodies into broad-spectrum inhibitors by tethering ACE2 to conserved epitope-targeting antibodies, showing potent neutralization against all variants including Omicron.

bioRxiv · Jan 24, 2022 · PreprintBiochemistry

Neutralizing antibodies targeting the SARS-CoV-2 receptor binding domain isolated from a naïve human antibody library

B. N. Bell, A. E. Powell, C. Rodriguez, J. R. Cochran, P. S. Kim

The paper isolates and characterizes three novel neutralizing antibodies against SARS-CoV-2 RBD from a naive human antibody library, showing they neutralize the virus in vitro.

bioRxiv · Jan 7, 2021Immunology

A derivative of the D5 monoclonal antibody that targets the gp41 N-heptad repeat of HIV-1 with broad tier-2 neutralizing activity

A. A. Rubio, M. V. Filsinger Interrante, B. N. Bell, C. L. Brown, C. C. LaBranche, D. C. Montefiori, P. S. Kim

This paper describes the engineering of a D5 monoclonal antibody variant, D5_AR, which shows enhanced neutralizing activity against tier-2 HIV-1 strains and improved potency in cells expressing FcγRI.

bioRxiv · Oct 23, 2020Immunology

The high-affinity immunoglobulin receptor FcγRI potentiates HIV-1 neutralization via antibodies against the gp41 N-heptad repeat

D. C. Montefiori, M. V. Filsinger Interrante, B. N. Bell, A. A. Rubio, J. G. Joyce, J. W. Shiver, C. C. LaBranche, P. S. Kim

This paper shows that the FcγRI receptor enhances HIV-1 neutralization by NHR-targeting antibodies, enabling neutralization of tier-2 viruses.

bioRxiv · Aug 27, 2020Immunology